Alzheimer disease in African American individuals: increased incidence or not enough data?

Research on racial differences in Alzheimer disease (AD) dementia has increased in recent years. Older African American individuals bear a disproportionate burden of AD and cognitive impairment compared with non-Latino white individuals. Tremendous progress has been made over the past two decades in our understanding of the neurobiological substrates of AD. However, owing to well-documented challenges of study participant recruitment and a persistent lack of biological data in the African American population, knowledge of the drivers of these racial disparities has lagged behind. Therapeutic targets and effective interventions for AD are increasingly sought, but without a better understanding of the disease in African American individuals, any identified treatments and/or cures will evade this rapidly growing at-risk population. In this Perspective, I introduce three key obstacles to progress in understanding racial differences in AD: uncertainty about diagnostic criteria, disparate cross-sectional and longitudinal findings; and a dearth of neuropathological data. I also highlight evidence-informed strategies to move the field forward.

Introduction

Today, one in eight older Americans (>65 years of age) are affected by Alzheimer disease (AD) dementia and related dementias, at an annual cost of more than US $200 billion[1]. With future population increases in the oldest age groups, estimates indicate that 13.5 million individuals in the USA will have AD by the year 2050. Thus, prevention of AD is a public health priority. The most at-risk population in the USA is also becoming increasingly racially and ethnically diverse[2], and a growing body of evidence suggests that older African American individuals bear a disproportionate burden of cognitive impairment and dementia compared with other racial and ethnic groups[3-5]. According to some estimates, the incidence of AD is almost twofold higher in older African American individuals than in older individuals of other minority racial and ethnic groups in the USA[1-4]; however, the reasons for the increased burden are unknown. African American individuals are under-represented in AD clinical research studies, particularly longitudinal studies that include racially relevant risk factors that reflect their lived experience and studies that include biomarkers and neuropathology. Therefore, the contributions of risk factors and disease pathologies to AD in this population are still poorly understood.

Throughout this perspective, the terms race and ethnicity are used. Both terms describe social constructs with no basis in biology, but in the medical literature, race is typically used to group people who are similar in ancestral background and/or share phenotypic features like skin colour. For example, in the US Census, five categories of race are officially recognized: white, Black or African American, Asian American, American Indian/Alaska Native, and Native Hawaiian/Pacific Islander. In contrast, ethnicity is used to group people who share common cultural traditions, languages and values regardless of racial classification (for example, people with cultural ties to Latin America are often referred to as being of Latino, Latina or Latinx ethnicity but can be of any race). In this Perspective, I specifically address the situation in the USA and use the term African American to refer to individuals who would be grouped by the US Census into the Black or African American category.

The ageing and dementia research community has identified a number of genetic, medical, and lifestyle factors that are associated with the risk of dementia. Although this knowledge, largely gathered from study cohorts that are overwhelmingly white, is generally assumed to characterize risk in all populations, we know very little about the drivers of disease in African American individuals. The preponderance of data from one population can lead to the false and potentially dangerous conclusion that that group represents some type of scientific norm that all other groups should be compared to. However, research on the drivers of AD in minoritized populations — that is, populations that have been systematically marginalized in society — is as important as research of drivers in the majority population, and should be the focus of studies, even if it does not explicitly inform us about racial differences.

The current evidence for higher rates of dementia among African American individuals is broad and has been comprehensively reviewed elsewhere[4,6,7]. It is generally well-accepted that in the USA race is a social construct based primarily on phenotypic traits that shape access to power and social and economic resources[8]. The effects of power differentials and social disadvantage might apply to other marginalized groups (for example, white individuals of low socioeconomic status, rural Americans, sexual and gender minorities, other racial or ethnic minorities, immigrants and people with disabilities); however, recent events related to the global coronavirus disease 2019 (COVID-19) pandemic, the public murder of George Floyd, and other instances of social unrest for African American people have made it clear that the AD disparities for this population in particular, have roots in structural and social determinants.

Despite the central role of genetics in AD, racial disparities in AD are not completely explained by genetics[9]. Indeed, reports have confirmed that AD-related genetic variants found in white individuals also exist in African American individuals, although disease-associated loci within the common pathways involved in AD aetiology (for example, immunity, lipid processing, intracellular trafficking) and the risk attributable to the loci might differ[10-12]. Social factors linked to race[13], prevalent vascular disease[6], disparities in years and quality of education[7], and unequal access to and/or inequitable use of health care[14] are increasingly recognized as having important roles in the excess risk of AD in African American individuals, even if they do not completely account for the disparities.

Ultimately, the disproportionate burden of AD in the African American population is likely to be caused by a complex interaction of socially patterned environmental exposures (that is, the social exposome) and biological factors that accumulate throughout the life course. The challenge for those of us working in the field will be to address the methodological barriers that hamper our progress in studies of racial differences, and to become more integrative in our study designs and approaches, bringing to bear the interdisciplinary talent and expertise that is needed to unravel the complexity of the disease.

Understanding racial differences

At least two scientific arguments exist for studying racial differences in AD. First, understanding why risk factors for AD in African American individuals differ from those in white individuals will help make the accumulated research on white individuals relevant for African American individuals. Second, understanding these differences might help us learn new information about AD overall, including information that could improve diagnosis and prognosis, and open the door for further scientific discovery. However, major obstacles to understanding racial differences in AD exist — some methodological in nature and others reflecting an extreme lack of data.

Neuropsychological test performance

One important obstacle involves the current standard of making the diagnosis. A clinical diagnosis of AD requires cognitive impairment in at least two domains of cognition, as assessed by standard neuropsychological tests, and severe enough loss of function to interfere with daily activities[15]. This threshold for diagnosis was developed in white older adults with the disease and is somewhat arbitrary for everyone regardless of race. However, substantial racial disparities are observed on standard neuropsychological tests, with older African American individuals tending to perform more poorly on a wide range of tests — particularly tests of executive function and visuospatial ability[16,17] — than older white individuals, even when matched for level of education[18]. Disproportionate performance below the diagnostic threshold on these tests among African American individuals is likely to contribute to higher clinical incidence of dementia in this population. The degree of correspondence between test performance (or clinical diagnosis) and the underlying pathology that causes dementia can be quite variable[19], possibly even more so for African American individuals[20], although the data addressing this question are limited. However, even beyond the lack of correspondence between clinical symptoms and pathology, an emerging body of research brings into question whether these racial differences in test performance actually indicate a higher incidence of AD in African American individuals than other ethnic or racial groups or whether another explanation exists.

First, as documented in numerous studies, educational and cultural experiences often bias neuropsychological test performance[21-24]. To circumvent this problem, clinicians and/or researchers sometimes rely on the use of race-based norms, which are normative standards for neuropsychological tests that are adjusted according to race. These norms are typically created by testing a large representative sample of people from the same racial group (either nationally representative or representative of the local setting) who vary along a range of characteristics that are important for neuropsychological tests such as years of education, and are used to judge and interpret test performance for that particular racial group. However, although race-based norms are helpful for increasing diagnostic accuracy in clinical settings, their use makes a number of assumptions about biological constructions of race that might lead to erroneous and potentially harmful interpretations of underlying racial differences[24]. Furthermore, use of these norms makes it virtually impossible to understand why such differences exist in the first place. The other strategy for dealing with biases in test performance is to adjust for factors that might influence performance in cross-sectional assessments. However, even when adjustments are made for the factors that make the measures less valid in African American individuals (for example, years of education or socioeconomic status), a host of other factors can influence test performance among African American individuals and are not typically considered when interpreting levels of cognitive impairment[25-27], especially in studies that compare African American individuals to white individuals[28,29]. For example, educational quality has been known for some time to be a stronger predictor of test performance among African American individuals than years of education[30,31]; a finding that has been consistently replicated over the years[32]. However, the field has struggled to document robust measures of education quality and such measures are rarely used to facilitate the interpretation of test results in the clinical context[33].

Interestingly, many of the factors that influence test performance in African American individuals, such as quality of education, and experiences of early-life educational segregation and discrimination, often seem to affect initial neuropsychological test performance but not cognitive decline. For example, a study published in 2019 (ref.[25]) found that African American individuals born in a southern US state (or living in that state at age 12 years) as determined by US Census geographic designations, performed at lower levels across five domains of cognitive performance than individuals born or living in a northern US state at age 12 years. State of birth also interacted with school segregation experience such that participants who lived in the South and attended a legally desegregated school had the lowest performance of any group, including participants who lived in the South and attended a segregated school or those who lived in the North and attended either type of school. Neither factor, state of birth or segregation experience, was related to cognitive decline; only baseline level of performance. These, and similar findings are consistent with the idea that factors particularly reflective of historical experiences of marginalized populations in the USA have an important negative impact on test performance and might contribute to claims of an increased risk of dementia in these populations.

Study design

Another obstacle is the discrepancy between the racial differences in AD observed in cross-sectional studies and those observed in longitudinal studies (Table 1). Most of the existing literature on race and cognition comes from cross-sectional studies, in which cognition is measured at one point in time and compared with that in a white comparison group. Such studies have consistently found lower performance on neuropsychological tests by African American individuals than age-matched and education-matched white individuals, irrespective of dementia status[7,16,22]. As highlighted above, a number of cultural and educational factors influence cognitive test performance and make the interpretation of racial differences in cross-sectional studies challenging. Although racial differences identified in cross-sectional studies could reflect stable differences in cognitive reserve, factors that influence cognitive reserve vary substantially across race[34] and might differentially impact late-life cognition and potentially exacerbate disparities. However, studies that use repeated observations for each person over time overcome the inherent challenges associated with using cross-sectional designs to study racial differences in cognition, as the biases that affect a single test measurement are typically constant over time and are therefore less likely to affect analyses of individual changes in cognitive performance[35]. Thus, change in cognitive function over time is more meaningful than static observations of cognitive function when comparing African American individuals and white individuals. Measuring change in cognition over time is also a more realistic reflection of the actual course of AD, which is characterized by progressive cognitive decline[36].

Table 1

Studies of age-related cognitive decline in Black or African American individuals and white individuals

Study	Population type	Proportion of participants Black or African American (%)	Mean Age (SD) (years)	Follow-up (years)	Outcome	Rate of decline in Black or African American participants compared with white participants
Sachs-Ericsson and Blazer (2005)[42]	Population-based	54	73 (6)	3	Short portable mental status questionnaire	Faster
Sloan and Wang (2005)[47]	Nationally representative	Not reported	>70	7	Telephone interview for cognitive status, word recall	Slower
Karlamangla et al. (2009)[46]	Nationally representative	8	77.1 (not reported)	9	Telephone interview for cognitive status, word recall	Slower
Masel and Peek (2009)[39]	Nationally representative	16	60 (3)	9	Telephone interview for cognitive status, word recall	Faster
Sawyer et al. (2009)[40]	Population-based	54	>65	10	Short portable mental status questionnaire	Faster
Castora-Binkley et al. (2015)[37]	Nationally representative	12	74 (7)	12	Telephone interview for cognitive status, word recall	Equivalent
Early et al. (2013)[45]	Convenience	29	78.4 (7.1)	3.9	Spanish and English Neuropsychological Assessment Scales (SENAS), episodic memory, executive function	Slower
Marsiske et al. (2013)[38]	Intervention	28	74 (6)	5	Memory, reasoning, visual processing speed, vocabulary, digit symbol substitution	Equivalent
Gross et al. (2015)[18]	Pooled sample of population-based and convenience	30	76 (8)	4	Latent factors from batteries of tests representing general cognitive performance, memory, and executive function	Slower
Wilson et al. (2015)[17]	Convenience	50	73 (not reported)	6.3	Rush battery, episodic memory, semantic memory, working memory, perceptual speed, visuospatial ability	Slower
Bryd et al. (2018)[41]	Nationally representative	32	54.1 (17.6)	25	Short portable mental status questionnaire	Faster
Weuve et al. (2018)[44]	Population-based	64	72.1 (6)	<18	Brief tests of global cognition, episodic memory, perceptual speed	Slower
Amariglio et al., 2020[43]	Convenience	16	72 (7)	1–7	Preclinical Alzheimer Cognitive Composite-5 (PACC-5)	Faster

SD, standard deviation.

In contrast to the results of cross-sectional studies, the results of longitudinal studies have been mixed. Some longitudinal studies in people without AD found equivalent rates of change in neuropsychological test performance in African American individuals and white individuals[37,38], others found faster decline in cognitive ability among African American individuals[39-43], and still others found slower decline in African American individuals[17,18,44-47]. The factors contributing to these discrepant findings are uncertain, but are likely to have involved a combination of methodological issues related to recruitment and study engagement, sample selection, study design, measurement (for example, outcome measures with ceilings or with unequal interval scaling) and survival[48-50]. Taken together, the results of longitudinal studies suggest that there are probably not strong racial differences in trajectories of cognitive ageing[17]. This observation is important because one might expect that the putative increased incidence of AD among African American individuals would be reflected in consistently faster rates of cognitive decline, the hallmark of a progressive neurodegenerative condition.

Lack of data

The last important obstacle in interpreting racial differences in AD, concerns the underlying pathology that causes dementia. Although neuropathological evaluation is still the gold standard for determining the presence and severity of common age-related pathologies in the post-mortem brain, few clinical–pathological studies have been conducted in older African American individuals. The majority of such studies used retrospective designs that included autopsies from medical examiners’ cases, which came to autopsy regardless of the manner of death, and included little information on pre-mortem clinical or cognitive status[51-54]. One study found that AD and Parkinson disease-related pathology was more common in white individuals than African American individuals, whereas the prevalence of cerebrovascular disease was higher in African American individuals than in white individuals[51]. Other studies found no racial differences in the prevalence of AD pathology[52,53,55,56]. In one post-mortem study of brains from 13 African American individuals with a clinical diagnosis of AD who received a comprehensive clinical evaluation before death, a wide spectrum of vascular disease and AD pathology was observed — more than half of the participants had a mixture of AD pathology and stroke[57]. In a sample of 122 participants with a diagnosis of clinical AD (41 African American individuals and 81 white individuals matched for age at death, sex, education, and cognitive status), mixed pathologies were far more common in African American individuals than white individuals[58]. Specifically, compared with white individuals, African American individuals with AD dementia were more likely to have AD pathology mixed with Lewy bodies or AD pathology mixed with Lewy bodies and infarcts. On average, African American individuals also had more severe arteriolosclerosis and atherosclerosis than white individuals. These results have since been replicated in a much larger sample of African American individuals and white individuals from the National Alzheimer’s Coordinating Center[59].

Most of the neuropathological studies discussed here enrolled African American individuals with dementia from a clinic setting; however, the recruitment of study participants, particularly African American individuals, from a specialty memory clinic is known to be prone to selection bias[6,49]. For example, because of fractured health-care relationships, mistrust and misconceptions about AD being a ‘normal part of ageing’[60], African American individuals are more likely to present to medical attention with behavioural problems, such as hallucinations, agitation and sleep disorders, than for memory problems[6]. Thus, longitudinal studies involving well-characterized community-dwelling African American participants who initially enrol without dementia need to be performed to examine racial differences in the underlying neuropathology of dementia. Interestingly, in such studies few racial differences in neuropathology have been observed[61].

Similar to the lack of neuropathology data from African American individuals, few AD biomarker studies have been performed in this population and the results have been mixed. To date, all cerebrospinal fluid (CSF) AD biomarker studies, including those performed in participants without AD or mild cognitive impairment (MCI), have found lower levels of phosphorylated tau181 and total tau[62-65] in African American individuals than in white individuals. However, studies of plasma and PET biomarkers in participants with and without AD found no difference in levels of tau between African American individuals and white individuals[66-68]. One study in people without dementia found higher amyloid PET burden in African American individuals than in white individuals[69] (Table 2). The reasons for these discrepancies are unclear but the studies that measured tau in the CSF included relatively small samples of African American individuals and might have been prone to selection bias, given that African American individuals are less likely than white individuals to agree to lumbar puncture[70]. In addition, the extent to which results are influenced by genetics or disease status (for example, MCI or AD) are unclear. Larger studies with representative samples of African American individuals with adjustment for the broad range of confounding factors are obviously needed.

Table 2

Studies of Alzheimer disease biomarkers in Black or African American individuals and white individuals

Study	Biomarker(s)	Number of Black or African American participants	Number of white participants	Biomarker levels in Black or African American participants compared with white participants
Gottesman et al. (2016)[69]	Aβ PET	141	188	Higher
Howell et al. (2017)[62]	CSF p-tau181 and t-tau	65	70	Lower
Garrett et al. (2019)[63]	CSF p-tau181 and t-tau	152	210	Lower
Morris et al. (2019)[64]	CSF p-tau181 and t-tau	97	816	Lower
Kumar et al. (2020)[65]	CSF p-tau181 and t-tau	30	50	Lower
Meeker et al. (2020)[66]	Aβ PET, tau PET and structural and functional MRI	70	434	No difference in tau PET, Aβ PET, or functional MRI; lower brain volume
Brickman et al. (2021)[67]	Plasma Aβ1–40, Aβ1–42, t-tau, p-tau181, p-tau217 and NfL; Aβ PETa	98	99	No difference in any biomarker
Rajan et al. (2021)[68]	Serum t-tau, NfL and GFAP	811	516	No difference in any biomarker

Aβ, amyloid-β, t-tau, total tau; p-tau, phosphorylated tau; NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein. aIncluded 100 Hispanic participants.

Strategies to move forward

Notwithstanding the challenges in interpreting racial differences in AD — and regardless of whether incidence of the disease is greater among African American individuals than white individuals — the burden of AD faced by the African American community is undeniable and represents an urgent public health issue. Understanding this issue and developing solutions will not be possible without actively cultivating a new narrative of ‘belonging’ in research for a population that has been historically marginalized and disenfranchized. A number of important steps should be taken to achieve these goals.

Recruitment of study cohorts

Although AD is viewed as an urgent public health issue in the USA, resulting in widespread support for and focus on the development of effective therapeutics, study cohorts are still shockingly and overwhelmingly homogeneous and white in terms of racial background. We can no longer afford to run research studies that do not reflect the diverse backgrounds and life experiences of the growing and increasingly diverse older adult US population. The scientific importance of enrolling people from under-represented populations in future studies is greater than the importance of enrolling people from groups already over-represented in our studies. Furthermore, we will learn more about the disease if we enrol participants with different risk factors and life experiences, as opposed to continuing to enrol participants who are similar to those we have already studied. A sustained culturally sensitive outreach effort and ongoing community-wide education will be required to overcome the barriers that underlie low representation in research among African American individuals[71]. Such efforts will be essential for achieving successful recruitment and high rates of follow-up, and for encouraging participants to consent to invasive procedures such as, organ donation, lumbar puncture and PET that are often included in AD research. The recruitment of diverse samples that are representative of the community should be the goal of such efforts; differential selection into a study by race or ethnicity could give rise to selection bias and exacerbate disparities[49]. Thus the study recruitment pipelines for African American individuals and white individuals must be intentionally designed so that they do not create an intractable selection bias.

Although examples exist of successful strategies for the recruitment and retention of participants from diverse backgrounds and life experiences[13,50], the field is desperately in need of novel methods. Prior research has identified several successful approaches to overcoming barriers that deter African American individuals and other minoritized groups from participating in research. First, recruitment must be based on a foundation of mutual trust and respect, establishing a collaborative, mutually beneficial relationship between the community and the research team. The essence of this approach is to think of the community and future study participants as partners, as opposed to research subjects. Second, employing team members with extensive ties to the community and including sufficient numbers of staff and investigators who reflect the individuals in the community is helpful. Third, identifying key contacts within the African American community for networking purposes is important, recognizing that stakeholders are not always religious clergy or political figures. Fourth, recruitment and retention must be coupled with culturally sensitive community education that empowers people, providing not only factual knowledge about the disease but also healthy lifestyle recommendations to motivate brain health and wellness. Last, because diverse populations often have a high prevalence of other chronic health conditions beyond AD, providing ancillary services and incentives for participation can help sustain the long-term relationships that are important for longitudinal studies[71,72].

In the last decade, innovative approaches that situate disparities within the historical inequities that caused them, while at the same time celebrating cultural assets, have also been shown to be effective strategies for increasing recruitment and engagement in research studies[73-76]. One study blended use of technology, neighbourhood walking and social reminiscence with the aim of maintaining cognitive health in older African American individuals with and without MCI[74]. Another study was a randomized trial within senior centres that evaluated the ability of a community choir programme called “The Community of Voices” to promote health and well-being[77]. Such approaches integrated with rigorous mixed methods can reveal unique participant perspectives about barriers to and facilitators of study participation, particularly for studies that require a higher level of commitment, such as brain autopsy[78,79].

The work is challenging, the work is labour intensive, and the work is expensive, but the work has to be done for therapeutics and/or a cure to be effective in all. Creating an inclusive and diverse participant pool requires extensive efforts in building relationships, establishing trust and creating a culturally sensitive space that is transparent for participants and community partners. This space often needs to be created before recruitment begins to firmly situate the work within the broader contexts of peoples’ lives and to align their interests and motivations with the goals of the research.

Structural risk factors

The examination of novel structural risk factors that are pertinent to the lived experience of older Black people[80] and grounded in the broader discourse regarding their unique history within the USA[81] is critical. For example, owing to institutionalized racism, neighbourhood racial residential segregation is an important societal characteristic that has caused a substantial proportion of the African American population to experience social environments where poverty and unemployment are the norm, where quality educational resources are lacking, and where social and physical deterioration make it difficult, if not impossible, to participate in behaviours that have been shown to protect brain health in late life[82,83]. High levels of neighbourhood-level social disadvantage and poverty, both common characteristics of most urban highly segregated cities, are associated with increased exposure to cardiovascular and metabolic health risk factors[84,85], lower cognitive scores and greater neuropathology, independent of individual socioeconomic status[86,87]. A more comprehensive understanding of race-specific stressors, particularly at the broader socioenvironmental level, and how they ‘get under the skin’ to affect brain health, could lead to a deeper insight into the social mechanisms underlying health disparities. Such insights could ultimately facilitate the development of interventions, policies and improved therapeutics to address health disparities. Progress simply will not happen if we continue to link racial differences to biology or genetics instead of the common social forces that cause differences, including poverty, racism and inequitable educational resources.

Although racial disparities in AD are manifest during later life, it is becoming increasingly clear that they are often rooted in early-life exposures[25,32]. A number of seminal theories suggest that racial and ethnic disparities in old age are likely to reflect a cumulative effect of disadvantage across the life course[88,89], and useful frameworks have been developed to foster investigation of structural and social determinants across different levels of analysis using a life course perspective[90,91]. Furthermore, because social determinants accumulate over time, the examination of risk factors from early life that shape opportunities and coping responses across the lifespan has the ability to uncover potentially novel factors that might have a role in the disease[92]. However, because of the inherent challenges involved in retrospective assessments of early life in older adults, studies that follow African American participants from young and mid-life to older age are needed. One example of such a study is Project Talent[93], which is a national longitudinal study that first surveyed high school students in 1960 and now follows up with participants decades later to measure ageing outcomes.

Conclusion: we need more data

A prevailing notion in the field is that African American individuals have a two to three times higher incidence of AD than white individuals. Although the burden of dementia is certainly high in the African American population, inconsistencies in the existing data and an important lack of data where it is most needed mean that we cannot be confident that the evidence supports this claim. Until and unless we change the narrative by increasing the number of studies that include African American participants, integrating risk factors that reflect the lived experience, and acquiring the biological data that will allow us to comprehensively examine the underlying mechanisms of disease, we will continue to have an incomplete understanding of racial differences in AD[4]. Importantly, we will come nowhere near developing therapeutics or at best, a cure, that will be effective in this population.